Search results: (10000)
News Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation concentrates, specifically concerning neurological complications related to bleeding.
News Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch observational pilot study examined residual concentrations of dabigatran in seniors of different ages with atrial fibrillation to clarify the relationship between study results and clinical practice.
News Frequency of Participation in Sports Activities and the Risk of Injury in Children with Hemophilia
In children with hemophilia, numerous positive effects of physical activity on their health have been described. However, due to concerns about injuries and joint bleeding, young hemophiliacs may often be limited in real participation in sports life. Results from published studies, however, indicate that with proper therapy, the frequency of injuries is similar to that of the general population.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News Efficacy of Reduced Dose Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis
The introduction of tumor necrosis factor inhibitors marked a breakthrough in the treatment of axial spondyloarthritis and other autoimmune diseases. One disadvantage of using these drugs can be increased susceptibility of patients to various infectious agents. The aim of the presented meta-analysis was therefore to determine whether a reduced dose of TNF inhibitors provides the same efficacy with a more favorable safety profile compared to the standard dosing regimen.
News Shared Decision Making Plays an Important Role in Dialysis
Peritoneal dialysis is very effective and comfortable for patients, yet it is used relatively little in the Czech Republic. Are we giving enough room to patients' preferences?
News Safety of Dabigatran in the Secondary Prevention of Venous Thromboembolism in Children
The direct thrombin inhibitor dabigatran is used by adult patients, among others, in the secondary prevention of venous thromboembolism (VTE). Its safety in the pediatric population was the focus of the international phase III study presented below.
News Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the treatment with pegylated recombinant factor VIII (rVIII) in real clinical practice. This is the most extensive observational study to date that evaluates the clinical effect of the treatment and at the same time compares the consumption of FVIII in people with hemophilia A who have changed medication from normal half-life (SHL) or extended half-life (EHL) concentrates to pegylated rVIII.
News Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.
News Dupilumab in the Treatment of Severe Asthma in Real-World Practice
A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.
News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations
In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new − even revolutionary − drugs into clinical practice.
News Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of netupitant and palonosetron (NEPA) versus palonosetron alone, both administered with dexamethasone. The results showed significantly better cost-effectiveness for NEPA.
News Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist − NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of chemotherapy-induced nausea and vomiting (CINV) for up to 5 days after its administration. Although the i.v. form of netupitant (fosnetupitant) + palonosetron (NEPA) did not lead to injection site reactions or anaphylactic reactions in a Phase III study, hypersensitivity and anaphylactic reactions have been described with other i.v. administered NK1RAs. Thus, the aim of the study recently published in the journal The Oncologist was to evaluate the safety and efficacy of i.v. NEPA in women with breast cancer treated with anthracycline and cyclophosphamide-containing chemotherapy.
News Trifluridine/tipiracil, regorafenib, or supportive therapy? Factors affecting the success of mCRC treatment
Currently, there are no biomarkers available to help decide, for a specific patient with refractory metastatic colorectal cancer (mCRC), whether therapy with trifluridine/tipiracil or regorafenib will be more effective and which patients will benefit the most from the treatment. A group of Czech oncologists presented the results of their analysis on this topic at the Gastrointestinal Symposium of the American Society of Clinical Oncology (ASCO) held in January 2020 in San Francisco.
News Physical Activity in Hemophiliacs and How to Ensure it Safely
Physical activity is beneficial − and this holds true for patients with hemophilia as well. New therapeutic modalities offer additional possibilities to optimize prevention so that, among other things, it allows hemophiliacs to engage in sports.
News Which Anticoagulant Treatment Do Patients Prefer?
For patients with atrial fibrillation (AF) for whom anticoagulant therapy is indicated for stroke prevention, good adherence to treatment is crucial. A recent study evaluated their perception of dabigatran treatment in comparison with vitamin K antagonists.
News Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure
In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed cardiovascular disease at study entry. In the following analysis, the authors focused on the benefit of empagliflozin in patients with different levels of risk for heart failure development.
News Impact of Oral Antidiabetics on Heart Failure
Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes and heart failure. This hypothesis is confirmed by the VALUE study, which primarily focused on arterial hypertension. Its results show that individuals with diabetes had a higher risk of heart failure compared to the risk of acute myocardial infarction.
News Dysregulation of microRNA Expression After Treatment with Anti-EGFR Antibodies
A team of researchers from Plzeň decided to verify whether treatment with anti-EGFR antibodies changes the expression of selected microRNAs in patients with metastatic colorectal carcinoma (mCRC). They have just published their findings in the autumn issue of the journal Cancer Genomics Proteomics.
News Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a relatively large Czech cohort of patients with acquired hemophilia A (AHA). The goal was to identify risk factors associated with early death and AHA relapse. Additionally, the authors addressed the question of the effect of higher doses of corticosteroids on treatment outcomes and patient mortality.
News Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?
The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic arthritis (PsA) after 3 years of use. The data below were presented as a poster presentation at the annual congress of the European League Against Rheumatism (EULAR), which was held virtually in June 2020.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?